Sanofi Launches Evoltra For Refractory Or Relapsed Acute Lymphoblastic Leukemia In Japan
This article was originally published in PharmAsia News
Executive Summary
Sanofi launched 20 mg intravenous infusion Evoltra (clofarabine) for the treatment of refractory or relapsed acute lymphoblastic leukemia (ALL) in Japan.